My Eye Doctor Found Early Plaquenil Retinopathy: Do I Have to Stop the Drug?
Early Plaquenil Retinopathy at a Glance
Usually yes, and almost never on your own. The label for Plaquenil (hydroxychloroquine) tells doctors to stop the drug when eye toxicity is suspected, and to watch the eyes closely after that.1 But the timing and the plan belong to you and the doctor who prescribed it. Eye care guidance says the choice to stop should be made with the patient and the prescribing doctor, not by the eye doctor alone.2 That doctor has to weigh what the drug is doing for your other illness. So ask for that talk this week. Do not just put the tablets down and wait.
Early means the change was found before it reached the layers that leave a permanent mark. Damage from this drug starts in the light sensing layer of the retina. Only later does it reach the pigment layer underneath and the very centre of sight.2 That order is the whole reason screening exists. Caught before the pigment layer breaks down, guidance describes only mild and limited change for about a year after the drug is stopped. Recognised after that layer is disrupted, it is likely to go on to thinning at the centre and loss of central sharpness.2 Early is the version worth having.
Nothing here has to be settled today. This is a slow process, measured in months and years, and your sight is not about to switch off. What it needs is a prompt decision rather than a drifting one, because the damage already there does not undo itself. Retinopathy from this drug is generally not reversible, except possibly at the very earliest stages.2 Treat it like a letter from the tax office: not a siren, but not a thing to leave in a drawer.
What Hydroxychloroquine Retinopathy Actually Is
Hydroxychloroquine collects slowly in the retina over years of daily use. It injures the photoreceptors first, the light sensing cells that turn light into signal. Only later does the support layer beneath them, the retinal pigment epithelium, break down.2 On a scan, the earliest sign is thinning of the outer retinal layers, usually in a ring a short way out from the centre of vision. The centre itself is often spared for a long time. That is why someone can have real damage and still read the bottom line of the eye chart.
Uncommon at sensible doses, and less rare than people expect after two decades. In a cohort of 3,325 people who took the drug for five years or more and were screened on the recommended schedule, retinopathy had appeared in about 3 of every 100 by 10 years and about 9 of every 100 by 15 years.3 An earlier study of 2,361 long term users found it in about 8 of every 100 overall. At doses of 4.0 to 5.0 mg per kilogram, risk stayed under 2 of every 100 in the first decade and rose towards 20 of every 100 after 20 years.4 You are in the group screening was built to find.
Doctors grade this by how far the damage has travelled, not by how bad your vision feels. Mild means patchy thinning of the light sensing layer, often visible only on a scan. Moderate means a fuller ring of thinning, with the pigment layer still intact. Advanced means the pigment layer has broken down, leaving the ring pattern older textbooks call a bull's eye. Among 81 people who developed retinopathy in that cohort of 3,325, 56 were mild, 17 moderate and 8 severe.3 Most cases that screening picks up sit at the mild end.
Why It Developed: Dose, Years, and the Other Risk Factors
Dose is the risk factor most under anyone's control. The prescribing label states that daily doses above 5 mg per kilogram of actual body weight raise the incidence of retinopathy, and that risk relates to total dose and length of treatment.1 Actual weight, not an ideal or target weight, is the number that counts. In the cohort of 3,325, the chance of retinopathy by 15 years tracked the average daily dose taken in the early years.3
| Average dose, early years | Retinopathy by 15 years | How to read it |
|---|---|---|
| More than 6 mg per kg | About 22 of every 100 | Roughly one in five |
| 5 to 6 mg per kg | About 11 of every 100 | Roughly one in nine |
| 5 mg per kg or less | About 3 of every 100 | Roughly one in 37 |
Those figures come from one large health system, and describe groups rather than you. Ask what your own dose per kilogram has been.
Time is the other half, and the half nobody can trade away. The drug builds up, so every extra year adds to the total. Using it for longer than 10 years raised the odds of retinopathy more than threefold in a study of 2,361 long term users.4 A UK screening clinic reviewing 368 patients also found that those with toxicity had been treated for longer, and at higher weight adjusted doses.5 That is why annual screening starts in earnest around the five year mark rather than on day one.
A few things raise the risk on top of dose and years. Reduced kidney function matters, because the kidneys clear much of the drug. A filtration rate cut by half roughly doubles the risk. Tamoxifen taken at the same time also raises risk, since tamoxifen is itself toxic to the retina.2 In the study of 2,361 users, kidney disease roughly doubled the odds of retinopathy, and tamoxifen raised them about four to five times.4 The label lists the same picture: more than five years of treatment, kidney impairment, tamoxifen use, and existing macular disease.1 None of this is a verdict on how careful you have been.
What You Can and Cannot Feel
Most people with early toxicity feel completely normal, and that is neither denial nor bad luck. Most patients who develop damage from this drug have no visual symptoms at all. A few notice small blind spots just off centre, usually while reading.2 The reason is structural. Damage begins in a ring around the centre of sight, so the sharpest part of your vision keeps working while the ring quietly thins. A normal eye chart result does not rule this out.
Symptoms tend to arrive late, once the pigment layer is involved. Difficulty reading and trouble seeing in dim light show up at that later stage, when the pigment layer is affected and the damage reaches towards the centre of sight.2 Letters dropping out of a word, a smudge just beside what you are looking at, or headlights that no longer help on a dark road are worth reporting. They do not mean your case is advanced. They mean your next appointment should be sooner.
How the Diagnosis Gets Confirmed
Two tests carry most of the weight, and they answer different questions. The scan, a cross section of the retina called an OCT, shows the thinning of the light sensing layer. The visual field test maps whether those same spots have lost sensitivity. A wide photograph of the natural glow of the pigment layer, called autofluorescence, is used alongside the scan to show damage further out from the centre.2
A single odd result is a question, not an answer. Field tests rely on attention and practice, so a first bad field can look normal on a repeat with nothing changed in the retina. Uncertain field changes should prompt repeat testing within a few months, or a check against objective tests. Unclear scan findings can be checked with a field test, or with a recording of how the retina responds to light.2 If your doctor repeated the tests and the pattern held, that is the confirmation step done properly.
Where the damage shows up is not the same for everyone, and the tests are chosen to match. Patients of European descent most often show the earliest damage in a ring close to the centre of vision. Patients of East Asian descent typically show it in a wider zone further out, so a broader field test pattern is used for them.2 If you were tested only with the narrow central pattern and your background suggests the wider one, it is fair to ask about that.
Deciding About the Drug: Stop, Lower, or Continue
Stopping removes what is causing the damage. The label instructs that if eye toxicity is suspected the drug should be stopped and the patient watched closely, because retinal changes and visual disturbance may progress even after treatment ends.1 That last clause is the honest part. Stopping does not repair what is done. It takes away the ongoing exposure, and it works best done early.
It comes up, and it is not yet settled science. Some recent data suggest that lowering the dose, for example halving the daily amount, may halt the acute progression of thinning. How long that effect lasts is unknown, and long term data are not yet available.2 That is an option to raise with your two doctors, not a reason to quietly cut your own tablets in half. If a lower dose is chosen, the follow up schedule usually tightens rather than relaxes.
This is the side of the ledger the eye clinic cannot see, and it is a genuine cost. In a randomised trial of 47 people with stable lupus, those switched to a dummy tablet had about 2.5 times the risk of a flare over six months. A severe flare needing withdrawal from the study happened in 5 of 22 on the dummy tablet, against 1 of 25 who continued.6 Across five Canadian lupus cohorts, flares or a need to step treatment back up ran at about 29 for every 100 patient years after stopping, against about 16 among matched patients who stayed on the drug.7 Both risks are real. That is why one person cannot make this call alone.
No injection, tablet, laser or supplement puts damaged photoreceptors back. Damage from this drug is generally not reversible, apart from possible slight recovery in a few of the very earliest cases. Screening aims to catch changes while they are still early and mild.2 A treatment claiming to restore this kind of damage runs ahead of the evidence. Your realistic goals are to halt further exposure and keep the vision you have.
What Happens to Your Vision From Here
The outlook for early, screen detected damage is reassuring where it counts. Your central reading vision is usually not what is at stake. When retinopathy is recognised before the light sensing band is extensively lost, guidance describes only mild and limited progression for about a year after the drug is stopped.2 In a small series of 11 patients followed 13 to 40 months after stopping, those found at an early patchy stage showed little change in acuity, fields or scan measurements, and the authors concluded that detection before visible changes at the back of the eye greatly reduces late progression.8 That series was small. Read it as encouraging rather than settled.
The picture changes once the pigment layer has broken down. That is why your doctor is relieved yours has not. Retinopathy first recognised at the stage of pigment layer disruption, with a visible bull's eye pattern, is likely to progress to thinning at the centre and eventual loss of central sharpness.2 In that same small series, patients with visible bull's eye damage kept losing the light sensing band for at least three years after the drug was stopped.8 You are on the better side of that line. Stopping now is how you stay there.
Follow up does not end when the tablets do, and how long it runs depends on how much damage was found. Guidance suggests that patients with extensive signs of toxicity when the drug is stopped be followed for several further years to check stability.2 In practice that means repeat scans and fields at intervals your retina specialist sets, each compared against the images on file. Keep going even if nothing changes. A stable run of scans over several years is the evidence that the decision worked. Ask for copies so a future doctor can see the baseline.
When to Call Your Eye Doctor
Some changes should move your appointment forward rather than wait for the annual slot. Ring your eye clinic within a few days if you notice any of these:
- A new blurred or missing patch just beside where you are looking.
- Letters dropping out of a line as you read.
- New difficulty seeing in dim light or when driving at night.
- Colours looking washed out compared with a few months ago.
- Anything that looks different in one eye when you cover the other.
Most such reports turn out to be something ordinary, such as a glasses change or a dry eye surface, and getting them checked is how those causes get fixed.
A different set of symptoms has nothing to do with this drug, and should not wait for a routine slot. Contact an eye doctor the same day, or an emergency service if you cannot reach one, for sudden vision loss, a curtain or shadow across your sight, a shower of new floaters, new flashing lights, or severe eye pain with a red eye. New floaters, flashing lights, or a curtain across the vision call for prompt examination, because a retinal tear or detachment is repaired more successfully when it is found early.9 These are uncommon, and treatable when caught quickly. That is why the call is worth making.
The most common failure after this diagnosis is not medical. It is two clinics each assuming the other is handling it. Ask your eye doctor to send the report and images to your prescriber, and take a copy to your next appointment yourself. Say plainly what you were told, including the grade, and ask what the plan is for the drug and the next scan. A decision written into both records is harder to lose.
Questions Patients Ask After an Early Retinopathy Diagnosis
No. Early damage from this drug affects a ring around the centre of sight, not the centre itself, and it does not take away all vision. Recognised before the light sensing band is extensively lost, guidance describes only mild and limited progression in the year after stopping.2 Loss of central sharpness is described mainly for damage found only after the pigment layer had broken down. Yours was found earlier, which is the point of screening. Keeping the follow up appointments is how that advantage is protected.
Mostly not, and it is better to hear that plainly. Retinopathy from this drug is generally not reversible, though slight improvement in the outer retina has been reported in a few isolated cases with very mild damage.2 What stopping does is remove the cause, so the process is not being fed any further. Think of it as putting the fire out rather than rebuilding the room. That is still worth doing quickly, because the sooner the exposure ends, the less there is to lose.
It is a fair question, and your doctor asks it too. Visual field tests in particular can look abnormal on a first attempt and normal on a repeat. Uncertain field changes should trigger repeat testing within a few months, or comparison against objective tests, and unclear scan findings can be checked with a field test or a multifocal electroretinogram.2 Ask directly whether your finding was confirmed on more than one test and on more than one visit. If it was not, ask whether it should be before the drug is changed.
Possibly, but that is a decision for your two doctors together, not a change to make yourself. Some recent data suggest that halving the daily amount may stop the acute progression of thinning. How long that effect holds is unknown, and long term data are not available.2 The label instructs that the drug be stopped, and the patient watched closely, when eye toxicity is suspected.1 So a lower dose is a conversation to have openly, with closer monitoring attached, not a quiet compromise.
There is a real chance of a flare, so it gets planned for rather than improvised. Across five Canadian lupus cohorts, poor outcomes were recorded at about 29 for every 100 patient years in those who came off the drug, and at about 16 for every 100 patient years in matched patients who did not.7 In practice your prescriber will usually book a review sooner than normal, tell you which symptoms mean call early, and decide in advance what to reach for if the disease stirs. Ask for that plan before you take the last tablet, not after.
Usually within the first year or two of repeat imaging. Change is measured against your own earlier scans, not a general standard. Guidance suggests following patients with extensive signs of toxicity for several years after stopping, to check stability.2 A single scan cannot show the direction of travel. That is why the appointment after next matters as much as the one you just had. Ask how often your retina specialist wants to see you, and what change would alter the plan.
More Questions About Living With This Diagnosis
For early, screen detected damage, almost always yes. The centre of sight is typically spared at this stage, and central sharpness is what reading and driving depend on most. Loss of central acuity is described for retinopathy that was not recognised until the pigment layer was disrupted.2 If you notice night driving getting harder, mention it, because that symptom belongs to the later stage and deserves a fresh look. Local driving rules vary, so ask your eye doctor what applies where you live.
Often yes, at least once, to confirm the finding and set the follow up. A retina specialist can match your images against the patterns this drug makes. They can also rule out other causes of thinning, such as age related change or an old macular problem. Your eye doctor can usually refer you directly. That referral matters more if you have another macular condition, because it makes the images harder to read.
Not worried, but they should check two things. The daily dose should sit at or below 5 mg per kilogram of actual body weight, since higher daily doses raise the incidence of retinopathy.1 A baseline eye examination is advised soon after the drug is begun, then annual screening, which may reasonably be deferred during the first five years when there are no significant risk factors.2 At 5 mg per kilogram or less, retinopathy appeared in about 3 of every 100 users by 15 years in one large cohort.3 A weight based dose and a kept appointment are most of the protection available.
Often it did catch it as early as the tests allow. Screening finds this at the stage a scan can see it, well before symptoms and usually before anything is visible at the back of the eye. Most patients with damage from this drug have no visual symptoms, so screening rather than symptoms is what detects it.2 Among 81 people who developed retinopathy in a screened cohort of 3,325, most cases were mild.3 If your screening intervals had gaps, that is worth reviewing calmly with your team.
Take this list to whichever appointment comes first, and ask for the answers in writing.
- What grade is my retinopathy, and which retinal layer is involved?
- Was the finding confirmed on a second test or a second visit?
- What has my daily dose been per kilogram of my actual weight?
- Are you advising that I stop, lower the dose, or continue for now, and why?
- Who will speak to my prescriber, and by when?
- If I stop, what is the plan if my other condition flares?
- How often do you want to repeat my scan and visual field?
- What change on those tests would alter the plan?
- Can I have copies of my scans and field results?
- U.S. Food and Drug Administration label via DailyMed (Concordia Pharmaceuticals) (2023). PLAQUENIL (hydroxychloroquine sulfate) tablets, prescribing information.
- American Academy of Ophthalmology, Clinical Statement (2025). Recommendations on Screening for Hydroxychloroquine Retinopathy (2025 revision).
- Annals of Internal Medicine (Melles RB, Jorge AM, Marmor MF, et al.) (2023). Hydroxychloroquine Dose and Risk for Incident Retinopathy: A Cohort Study.
- JAMA Ophthalmology (Melles RB, Marmor MF) (2014). The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.
- Cureus (Milad M, Kwok C, Wong O, Bohn M) (2025). Hydroxychloroquine Retinopathy in a UK Single-Centre Cohort: A Retrospective Study of Risk Factors and Dosing Trends.
- New England Journal of Medicine (The Canadian Hydroxychloroquine Study Group) (1991). A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.
- Arthritis Care and Research (Almeida-Brasil CC, et al.) (2022). Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decision-Making in Systemic Lupus Erythematosus Treatment?.
- JAMA Ophthalmology (Marmor MF, Hu J) (2014). Effect of disease stage on progression of hydroxychloroquine retinopathy.
- American Academy of Ophthalmology, Preferred Practice Pattern (Retina/Vitreous Panel) (2025). Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern.